Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 2/20 | 0.54 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CTSD | P07339 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2069250 | 1.00 | MTNR1A (0.54) | MTNR1AMTNR1BPOLBSMN1; SMN2KDM4E | |
| SCHEMBL2069117 | 0.86 | MTNR1A (0.51) | MTNR1AMTNR1BPOLBSMN1; SMN2KDM4E | |
| SCHEMBL2069498 | 0.86 | MTNR1A (0.51) | MTNR1AMTNR1BPOLBSMN1; SMN2KDM4E | |
| SCHEMBL14784609 | 0.79 | MTNR1A (0.47) | MTNR1AMTNR1BTSHRKMT2AHPGD | |
| SCHEMBL6068594 | 0.76 | CYP1A2 (0.54) | MTNR1AMTNR1BSMN1; SMN2KDM4ELMNA | |
| SCHEMBL2206369 | 0.76 | MTNR1A (0.47) | MTNR1AMTNR1BPOLBLMNACYP1A2 | |
| SCHEMBL6068589 | 0.76 | CYP1A2 (0.54) | MTNR1AMTNR1BSMN1; SMN2KDM4ELMNA | |
| SCHEMBL6068590 | 0.76 | CYP1A2 (0.54) | MTNR1AMTNR1BSMN1; SMN2KDM4ELMNA | |
| SCHEMBL2207267 | 0.76 | MTNR1A (0.47) | MTNR1AMTNR1BPOLBLMNACYP1A2 | |
| SCHEMBL9272577 | 0.75 | MTNR1A (0.47) | MTNR1AMTNR1BPOLBSMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902381-B2 | Synthesising method and benzoxathiepine intermediates | PIERRE FABRE MEDICAMENT (FR) | 2011-03-08 | — | — | US | disclosed |
| US-7902381-B2 | Synthesising method and benzoxathiepine intermediates | PIERRE FABRE MEDICAMENT (FR) | 2011-03-08 | — | — | US | disclosed |
| US-7902381-B2 | Synthesising method and benzoxathiepine intermediates | PIERRE FABRE MEDICAMENT (FR) | 2011-03-08 | — | — | US | disclosed |
| US-20080234499-A1 | Synthesising Method and Benzoxathiepine Intermediates | PIERRE FABRE MEDICAMENT (FR) | 2008-09-25 | — | — | US | disclosed |
| US-20080234499-A1 | Synthesising Method and Benzoxathiepine Intermediates | PIERRE FABRE MEDICAMENT (FR) | 2008-09-25 | — | — | US | disclosed |
| EP-1735297-B1 | SYNTHESISING METHOD AND BENZOXATHIEPINE INTERMEDIATES | PF MEDICAMENT (FR) | 2007-10-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234499-A1 | Synthesising Method and Benzoxathiepine Intermediates | CYP2F1, CYP2E1, CBR1 | MTNR1A 172/4885MTNR1B 225/4885POLB 3062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.